News

Aclarion Announces Publication of 2YR Outcomes in Groundbreaking Clinical Trial

The success rate at 2 years for discogenic low back pain surgeries was 85% for patients whose treatment strategy was consistent with Nociscan-identified discs, a 22 percentage point improvement over patients whose treatment strategy was inconsistent with Nociscan-identified discs (85% vs. 63%; p=0....

Exai Bio Presents New Non-Small Cell Lung Cancer Early Detection Data at the American Association for Cancer Research (AACR) 2023 Annual Meeting

Exai Bio today announced new data demonstrating that its novel RNA- and AI-based platform detected non-small cell lung cancer with high accuracy, at the earliest stages and for the smallest tumors, in both training and validation cohorts. In the independent validation cohort, stage I sensitivity...

Aer Therapeutics Closes $36 Million Series A to Advance Development of AER-01, an Innovative Mucolytic for the Treatment of Lung Diseases

Aer Therapeutics, a biopharmaceutical company developing novel inhaled treatments for muco-obstructive lung diseases, today announced the closing of a $36 million Series A financing. Funding was received from a syndicate of premier life science industry investors, including Canaan, OrbiMed, and...

The First FDA-Approved Video Game Was Developed in San Francisco

A video game prototype developed by Dr. Adam Gazzaley’s lab, called NeuroRacer, found that playing the 3D race car game improved cognitive performance in healthy older adults. The technology underlying that game is the foundation for EndeavorRx, which is made for children ages 8-12 with ADHD.  ...

Sonoma Biotherapeutics and Regeneron Announce Collaboration to Discover, Develop and Commercialize Therapies for Autoimmune Diseases

Sonoma Biotherapeutics is to receive $75 million upfront, inclusive of $45 million cash and $30 million equity investment; with the potential for an additional $45 million development milestone payment. Sonoma Bio was founded by Jeff Bluestone, PhD, and Qizhi Tang, PhD, both UCSF researchers.

Exai Bio and Quantum Leap Healthcare Collaborative Announce Expanded Participation in I-SPY 2 Trial to Advance Exai’s Novel RNA-based Liquid Biopsy Platform in Breast Cancer

The expanded agreement is based on positive initial data using Exai’s platform in the trial, which demonstrated that oncRNAs were a significant predictor of patient outcomes.

UCSF Speakers Reach Record Numbers at 2023 Precision Medicine World Conference

UC San Francisco scientists, experts and thought leaders participated in 32 presentations and panels over the 3-day Precision Medicine World Conference (PMWC) held January 25-27, 2023. The forum drew more than 2,000 people from around the world from various sectors to foster collaboration, expand...

ClearPoint Neuro Announces Exclusive Multi-Year Licensing Agreement with UCSF for Innovative Intra-Cerebral Cellular Delivery Platform

ClearPoint Neuro, a global therapy-enabling platform company providing navigation and delivery to the brain, today announced an exclusive multi-year licensing agreement of intellectual property from UC San Francisco (UCSF) through its Innovation Ventures group to develop and commercialize a...

EpiBiologics Launches with $50 million to Advance Next-Generation Protein Degradation Platform

EpiBiologics, a biotechnology company building a next-generation antibody-based protein degradation platform for membrane and extracellular drug targets, launched today with $50 million in Series A funding.

MindRhythm's EPISODE-PS Initial Trial Results are Published

MindRhythm Inc, in partnership with Wayne State University School of Medicine in Detroit, Michigan, today announces the first publication of results from the hEadPulse for Ischemic StrOke DEtection Prehospital Study (EPISODE-PS) trial. MyndRhythm Inc., was co-founded by UCSF researcher Dr. Wade...